Rob Davis

“We're not there yet, but we're moving in a direction with technology that's really unprecedented.”

Rob Davis · said 2026-10-14 · reported 2026-10-14

Davis said the companies are not yet at the point of a cure but are moving in an unprecedented direction with the technology.

“We're doing it in our clinicals, and I only see improvement going forward.”

Rob Davis · said 2026-10-14 · reported 2026-10-14

Davis said Merck is already administering the personalized cancer vaccine in clinical trials and expects improvement going forward.

“We are going to drive for improvement, but right now the focus really is, let's make sure we have the supply ready, we have the market ready to bring this important innovation to the market, and then we'll talk about how do we accelerate,”

Rob Davis · said 2026-10-14 · reported 2026-10-14

Merck CEO Rob Davis told CNBC in an exclusive interview that he expects the company's personalized cancer vaccine with Moderna to get faster to manufacture over time.

“I'm actually very confident that we're not going to have complexities in getting this to patients in a very timely fashion,”

Rob Davis · said 2026-10-14 · reported 2026-10-14

Davis acknowledged manufacturing the personalized cancer vaccine is a complex system but said Merck and Moderna have the process down to a tight science.

“But I do think over time you're going to see that timeline shortened.”

Rob Davis · said 2026-10-14 · reported 2026-10-14

Davis said he expects the current six-week timeline for manufacturing the personalized cancer vaccine to shorten over time.

“You like to talk that maybe you can start moving toward talking about a cure,”

Rob Davis · said 2026-10-14 · reported 2026-10-14

Davis discussed the possibility of eventually moving toward talking about a cure with Merck and Moderna's personalized cancer vaccine.